Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...

Mineralys Therapeutics' lorundrostat met key Phase 3 and Phase 2 trial endpoints for hypertension, showing significant blood ...

The management of HTN in patients with CHF is challenging. Drugs such as β-blockers, angiotensin-converting enzyme inhibitiors, angiotensin receptor blockers, aldosterone receptor blockers ...

Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met ...

SCRATCH-HTN aims to explore a new way of managing high blood pressure (BP), specifically ... and managing high BP is a key focus of treatment for cardiovascular diseases. Antihypertensive drugs are ...

Propranolol and metoprolol are beta-blockers taking to treat certain heart conditions. Learn more about their similarities ...